ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
2.060
+0.100 (5.10%)
At close: Jun 24, 2025, 4:00 PM
2.060
0.00 (0.00%)
Pre-market: Jun 25, 2025, 4:00 AM EDT

Company Description

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.

ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ABVC BioPharma, Inc.
ABVC BioPharma logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 19
CEO Uttam Patil

Contact Details

Address:
44370 Old Warm Springs Boulevard
Fremont, California 94538
United States
Phone 510 668 0881
Website abvcpharma.com

Stock Details

Ticker Symbol ABVC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001173313
CUSIP Number 00091F106
ISIN Number US00091F3047
Employer ID 26-0014658
SIC Code 2834

Key Executives

Name Position
Dr. Uttam Yashwant Patil Ph.D. Chief Executive Officer and Interim Chief Financial Officer
Eugene Jiang Chairman and Chief Business Officer
Dr. Tsung-Shann Jiang EMBA, Ph.D. Chief Scientific Officer, Chief Strategy Officer and Director

Latest SEC Filings

Date Type Title
Jun 4, 2025 8-K Current Report
Jun 3, 2025 SCHEDULE 13D Filing
May 30, 2025 8-K/A [Amend] Current report
May 27, 2025 POS AM Post-Effective amendments for registration statement
May 27, 2025 POS AM Post-Effective amendments for registration statement
May 27, 2025 POS AM Post-Effective amendments for registration statement
May 22, 2025 S-3 Registration statement under Securities Act of 1933
May 20, 2025 EFFECT Notice of Effectiveness
May 20, 2025 EFFECT Notice of Effectiveness
May 16, 2025 DEF 14A Other definitive proxy statements